Company intelligence / Profile preview

Lipdro Therapeutics

Alberta, Canada

Ownership: Private
Development stage: Other

Overview

Lipdro Therapeutics was a private biotech company that developed a pre-clinical platform targeting interleukin-32 (IL-32) for chronic kidney disease, particularly diabetic chronic kidney disease. The company was acquired by Arch Biopartners on September 17, 2025, following which its founder, Dr. Justin Chun, joined Arch to continue leading the IL-32 program.

Therapeutic areas: Nephrology
Modalities: Small molecule
Industry: Biotech

Partnerships

National Research Council of CanadaArch Biopartners

Beyond the preview

Go deeper on Lipdro Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipdro Therapeutics.

Explore the full profile